Literature DB >> 32932309

Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.

Diamantis I Tsilimigras1, Rittal Mehta1, Anghela Z Paredes1, Dimitrios Moris1, Kota Sahara1, Fabio Bagante1,2, Francesca Ratti3, Hugo P Marques4, Silvia Silva4, Olivier Soubrane5, Vincent Lam6, George A Poultsides7, Irinel Popescu8, Razvan Grigorie8, Sorin Alexandrescu8, Guillaume Martel9, Aklile Workneh9, Alfredo Guglielmi2, Tom Hugh10, Luca Aldrighetti3, Itaru Endo11, Gaya Spolverato12, Cillo Umberto12, Timothy M Pawlik1.   

Abstract

OBJECTIVE: The objective of the current study was to define surgical outcomes after resection of multinodular hepatocellular carcinoma (HCC) beyond the Milan criteria, and develop a prediction tool to identify which patients likely benefit the most from resection.
BACKGROUND: Liver resection for multinodular HCC, especially beyond the Milan criteria, remains controversial. Rigorous selection of the best candidates for resection is essential to achieve optimal outcomes after liver resection of advanced tumors.
METHODS: Patients who underwent resection for HCC between 2000 and 2017 were identified from an international multi-institutional database. Patients were categorized according to Milan criteria status. Pre- and postoperative overall survival (OS) prediction models that included HCC tumor burden score (TBS) among patients with multinodular HCC beyond Milan criteria were developed and validated.
RESULTS: Among 1037 patients who underwent resection for HCC, 164 (15.8%) had multinodular HCC beyond the Milan criteria. Among patients with multinodular HCC, 25 (15.2%) patients experienced a serious complication and 90-day mortality was 3.7% (n = 6). Five-year OS after resection of multinodular HCC beyond Milan criteria was 52.8%. A preoperative TBS-based model (5-year OS: low-risk, 73.7% vs intermediate-risk, 45.1% vs high-risk, 13.1%), and postoperative TBS-based model (5-year OS: low-risk, 80.1% vs intermediate-risk, 37.2% vs high-risk, not reached) categorized patients into distinct prognostic groups relative to long-term prognosis (both P < 0.001). Pre- and postoperative models could accurately stratify OS in an external validation cohort (5-year OS; low vs medium vs high risk; pre: 66.3% vs 25.2% vs not reached, P = 0.012; post: 61.4% vs 42.5% vs not reached, P = 0.045) Predictive accuracy of the pre- and postoperative models was good in the training (c-index; pre: 0.68; post: 0.71), internal validation (n = 2000 resamples) (c-index, pre: 0.70; post: 0.72) and external validation (c-index, pre: 0.67; post 0.68) datasets. TBS alone could stratify patients relative to 5-year OS after resection of multinodular HCC beyond Milan criteria (c-index: 0.65; 5-year OS; low TBS: 70.2% vs medium TBS: 54.7% vs high TBS: 16.7%; P < 0.001). The vast majority of patients with low and intermediate TBS were deemed low or medium risk based on both the preoperative (98.4%) and postoperative risk scores (95.3%).
CONCLUSION: Prognosis of patients with multinodular HCC was largely dependent on overall tumor burden. Liver resection should be considered among patients with multinodular HCC beyond the Milan criteria who have a low- or intermediate-TBS.

Entities:  

Mesh:

Year:  2020        PMID: 32932309     DOI: 10.1097/SLA.0000000000004346

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  6 in total

1.  A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection.

Authors:  Jianhua Wang; Zeguo Chen; Liheng Wang; Sijia Feng; Qixuan Qiu; Dongdong Chen; Nianfeng Li; Yao Xiao
Journal:  Sci Rep       Date:  2022-05-23       Impact factor: 4.996

2.  A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Yi-Hsiang Huang; Jia-I Liao; Chien-Wei Su; Ming-Chih Hou; Teh-Ia Huo
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

3.  Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c.

Authors:  Yi-Ming Li; Cong Xu; Bo Sun; Fang-Jing Zhong; Momo Cao; Lian-Yue Yang
Journal:  Cancer Cell Int       Date:  2022-04-23       Impact factor: 6.429

4.  Sema3d Restrained Hepatocellular Carcinoma Progression Through Inactivating Pi3k/Akt Signaling via Interaction With FLNA.

Authors:  Yiming Li; Cong Xu; Bo Sun; Fangjing Zhong; Momo Cao; Lianyue Yang
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

5.  Radiofrequency Ablation versus Transarterial Chemoembolization for Hepatocellular Carcinoma within Milan Criteria: Prognostic Role of Tumor Burden Score.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Yi-Hsiang Huang; Jia-I Liao; Chien-Wei Su; Ming-Chih Hou; Teh-Ia Huo
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

6.  Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study.

Authors:  Hui Li; Rongqiang Liu; Haizhou Qiu; Yang Huang; Wenbin Liu; Jiaxin Li; Hong Wu; Genshu Wang; Dewei Li
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.